BrainSee: Predicting Dementia Before Symptoms Steal Tomorrow
What is BrainSee? BrainSee is a non-invasive, FDA-approved AI software that analyses brain MRI scans and cognitive test scores to predict the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer’s dementia within five years. The software generates a personalised risk score between 0 and 100, with lower scores indicating a lower risk […]
Feature Categories
What is BrainSee?
BrainSee is a non-invasive, FDA-approved AI software that analyses brain MRI scans and cognitive test scores to predict the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia within five years. The software generates a personalised risk score between 0 and 100, with lower scores indicating a lower risk of progression.
This tool helps clinicians make informed decisions about early interventions and monitoring strategies. BrainSee is designed to be user-friendly, providing results on the same day the clinical data is submitted. Its integration into routine clinical practice offers a significant advancement in dementia care.
Why Leading Healthcare Teams Trust BrainSee
- Received FDA Breakthrough Device Designation in 2021, recognising the technology's potential to address unmet medical needs in Alzheimer's disease prediction
- Granted FDA De Novo approval in January 2024 as the first prognostic test for predicting progression from mild cognitive impairment to Alzheimer's dementia
- Demonstrated 99.5% test-retest consistency correlation coefficient, indicating high reliability and reproducibility of results
- FDA approved post-market surveillance study in May 2025 to continue monitoring real-world performance and safety
- Backed by pharmaceutical giant Eisai, Y Combinator, and IT-Farm in 2020 funding round, bringing credibility through established healthcare investor support
- Holds U.S. patents for proprietary brain MRI technology with patents pending in Europe, Japan, and China
- Selected for Medicare's GUIDE Model program through partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition, demonstrating government healthcare program endorsement
- Partnered with CABHI (Centre for Aging and Brain Health Innovation, powered by Baycrest Institute) for deployment in memory clinics across the U.S. and Canada
Top 3 Pain Points BrainSee Fixes in Healthcare
| Problem | How BrainSee Solves It |
|---|---|
| 1. Late detection of cognitive decline | BrainSee analyzes brain MRI and cognitive assessments to identify early-stage dementia risk, enabling timely interventions before symptoms worsen. |
| 2. Uncertainty in prognosis for aMCI patients | Generates a personalized risk score (0–100) to predict progression from amnestic mild cognitive impairment to Alzheimer’s within five years, giving clinicians actionable insights. |
| 3. Limited clinical decision support for early intervention | Provides same-day results and an intuitive interface, helping healthcare providers make informed decisions on monitoring, care planning, and treatment strategies. |
Feature Category Summary: BrainSee
| Feature Category | Summary | Association (YES, NO, NA) |
|---|---|---|
| Regulatory-Ready | BrainSee is an AI-based software as a service platform that has received De Novo FDA approval as a first-in-class clinical test to predict progression from amnestic mild cognitive impairment to Alzheimer’s disease, and the FDA decision summary describes it as prescription-only software with defined indications for use, risk controls, and post-market surveillance, which implies a validated, auditable, and quality-managed lifecycle under FDA medical device regulations. | YES |
| Clinical Trial Support | Peer-reviewed and preprint descriptions state that BrainSee is designed to provide objective early diagnosis and prognosis of Alzheimer’s disease and to enable correct patient selection and stratification in Alzheimer’s clinical trials, and FDA-approved post-market study documentation emphasizes using BrainSee to validate performance across diverse populations and to support pharmaceutical companies in identifying optimal candidates for next-generation Alzheimer’s clinical trials. | YES |
| Supply Chain & Quality | Public materials focus on BrainSee as AI software for image analysis, prognosis, and clinical trial enablement, and there is no mention of features for managing physical product manufacturing, serialization, counterfeit detection, or pharmaceutical supply chain quality operations. | NA |
| Efficiency & Cost-Saving | BrainSee is described as a noninvasive software test that uses existing clinical MRI and standard cognitive assessments to provide objective prognostic scores, which is intended to avoid unnecessary invasive or costly biomarker testing, reduce diagnostic uncertainty, and streamline patient workups and monitoring workflows. | YES |
| Scalable / Enterprise-Grade | BrainSee is characterized as an AI-based software as a service or enterprise software platform for whole-brain MRI analysis and high-throughput, robust analysis of images from different sources, but there is no explicit evidence of large-scale deployments in multiple named pharma or biotech enterprises with documented enterprise-wide rollouts. | NA |
| HIPAA Compliant | Available press releases and scientific descriptions focus on technical performance, clinical validity, and regulatory approval, and do not explicitly claim HIPAA compliance, HITRUST certification, or adherence to specific healthcare privacy frameworks for the BrainSee platform. | NA |
| Clinically Validated | FDA De Novo approval is based on clinical evidence that BrainSee predicts progression from amnestic mild cognitive impairment to Alzheimer’s disease within five years with high accuracy, and published and preprint studies report approximately 90 percent accuracy, robust performance across multi-site MRI data, and ongoing FDA-mandated seven-year post-market studies to further validate safety and effectiveness in socio-demographically diverse populations. | YES |
| EHR Integration | Descriptions of the BrainSee Platform emphasize cloud-based test administration, remote doctor visits, cognitive assessments, MRI referral workflows, and result reporting, but there is no specific mention of technical integration with named electronic health record systems or standardized clinical data interfaces such as HL7 or FHIR. | NA |
| Explainable AI | Technical and regulatory summaries focus on predictive performance and clinical utility of BrainSee’s whole-brain image analysis and AI algorithms, and there is no explicit claim that the software provides case-level explanations, feature importance maps, or other explainability outputs for clinicians beyond the prognostic score and risk categorization. | NA |
| Real-Time Analytics | BrainSee is presented as an AI-powered diagnostic and prognostic service that analyzes MRI and clinical data to generate results, but no documentation describes real-time or streaming analytics, continuous monitoring dashboards, or sub-second processing intended for real-time clinical decision support beyond standard turnaround of a software test. | NA |
| Bias Detection | The FDA-approved seven-year post-market surveillance study aims to evaluate BrainSee’s safety and effectiveness in a socio-demographically diverse patient population, but there is no documentation of built-in product capabilities for automatic detection, quantification, or reporting of algorithmic bias across demographic subgroups within the BrainSee user interface or analytics. | NA |
| Ethical Safeguards | BrainSee is regulated as prescription-only medical device software used as a clinical test ordered by qualified physicians, and the platform offers controlled clinical workflows such as remote doctor visits and physician-mediated test ordering and interpretation, but there is no explicit description of configurable consent management modules, human-in-the-loop override settings beyond standard physician use, or embedded policy-based use-case restriction tooling. | NA |
Risks & Limitations: BrainSee
-
Site/scanner variability: MRI protocol differences and scanner models can affect model performance — require initial QC and possible local recalibration.
-
Population generalizability: models trained on specific cohorts may underperform on different demographics—pilot validation is essential.
-
Not a molecular diagnostic: MRI-based risk scores are prescreen/stratification tools; confirmatory PET/CSF or validated blood biomarkers remain required for definitive molecular diagnosis where indicated.
-
Regulatory & reimbursement: clinical utility and reimbursement depend on prospective evidence and payer acceptance; include these considerations in rollout planning.
Tags
Share This AI Tool
Get a neutral, no obligation view of whether this AI tool fits your portfolio
Stephen
Founder of HealthyData.Science · 20+ years in life sciences compliance & software validation · MSc in Data Science & Artificial Intelligence.